Adjuvant Pembrolizumab in Resected Stage III Melanoma Reply

被引：0
|
作者：
Eggermont, Alexander M. M. [1 ]
Robert, Caroline [1 ]
Suciu, Stefan [2 ]
机构：
[1] Gustave Roussy Canc Campus Grand Paris, Villejuif, France
[2] European Org Res & Treatment Canc Headquarters, Brussels, Belgium
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 379卷 / 06期
关键词：
HIGH-RISK;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：593 / 595
页数：4
相关论文
共 50 条
  • [21] Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study
    Tao Li
    Dong-Dong Jia
    Li-Song Teng
    Investigational New Drugs, 2020, 38 : 1334 - 1341
  • [22] Impact of adjuvant immunotherapy in resected stage II/III/IV melanoma: A single center experience
    Sevillano Tripero, Alberto Rafael
    Ortiz, Carolina
    Lostes, Julia
    Bodet, Domingo
    Ferrandiz, Carla
    Bassas, Patricia
    Chiquillo, Paula
    Villacampa, Guillermo
    Vega-Cano, Kreina Sharela
    Garcia-Patos, Vicente
    Recio, Juan
    Munoz-Couselo, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Real-world outcomes of patients with resected stage III melanoma treated with adjuvant therapies
    Dima, Danai
    Lopetegui-Lia, Nerea
    Ogbue, Olisaemeka
    Osantowski, Bennett
    Ullah, Fauzia
    Jia, Xuefei
    Song, Jung Min
    Gastman, Brian
    Isaacs, James
    Kennedy, Lucy Boyce
    Funchain, Pauline
    CANCER MEDICINE, 2024, 13 (12):
  • [24] Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma-A Discrete Choice Experiment
    Livingstone, Ann
    Howard, Kirsten
    Menzies, Alexander M.
    Long, Georgina V.
    Stockler, Martin R.
    Morton, Rachael L.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2023, 16 (05): : 497 - 513
  • [25] Preferences for adjuvant immunotherapy in patients with resected stage III melanoma: A discrete choice experiment.
    Livingstone, Ann
    Menzies, Alexander M.
    Howard, Kirsten
    Stockler, Martin R.
    Morton, Rachael L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma
    Lorenzi, Maria
    Arndorfer, Stella
    Aguiar-Ibanez, Raquel
    Scherrer, Emilie
    Liu, Frank Xiaoqing
    Krepler, Clemens
    JOURNAL OF DRUG ASSESSMENT, 2019, 8 (01) : 135 - 145
  • [27] Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma
    Sullivan, Ryan Joseph
    LANCET, 2020, 395 (10236): : 1524 - 1525
  • [28] Update on Adjuvant Therapy in Late-Stage Resected Melanoma
    Tarhini, Ahmad A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (12) : 753 - 755
  • [29] Surgical Outcomes of SWOG1801: Neoadjuvant/adjuvant Versus Adjuvant Pembrolizumab for Resectable Stage III-IV Melanoma
    Lowe, Michael C.
    Hyngstrom, John R.
    Wright, Gerald P.
    Othus, Megan
    Sharon, Elad
    Kirkwood, John M.
    Ribas, Antoni
    Patel, Sapna P.
    Sondak, Vernon K.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S49 - S49
  • [30] Immunotherapy versus targeted therapy in the adjuvant setting for resected stage III melanoma: A single institution study.
    Dima, Danai
    Lopetegui-Lia, Nerea
    Ogbue, Olisaemeka
    Osantowski, Bennett
    Ahmed, Ramsha
    Basali, Diana
    Chamseddine, Fatimah
    Eicher, Donald Matthew
    Song, Jung Min
    Gastman, Brian
    Kennedy, Lucy Boyce
    Funchain, Pauline
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345